{"id":"drug-either-ppis-or-h2ra-and-prokinetics","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea or constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3508697","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PPIs irreversibly inhibit the H+/K+-ATPase pump in gastric parietal cells, while H2RAs competitively block histamine H2 receptors to reduce acid secretion. Prokinetics (such as metoclopramide or domperidone) enhance gastric muscle contractions and accelerate food movement through the stomach. The combination addresses both acid-related symptoms and motility dysfunction in gastroesophageal reflux disease and related conditions.","oneSentence":"This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:44.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Functional dyspepsia with impaired gastric motility"}]},"trialDetails":[{"nctId":"NCT02703896","phase":"PHASE4","title":"Prophylaxis for Aspiration of Gastric Contents.","status":"COMPLETED","sponsor":"King Saud University","startDate":"2012-01","conditions":"Pulmonary Aspiration of Gastric Contents","enrollment":1920}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5384,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Drug treatment","lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine"],"phase":"marketed","status":"active","brandName":"Drug either PPIS or H2RA and prokinetics","genericName":"Drug either PPIS or H2RA and prokinetics","companyName":"King Saud University","companyId":"king-saud-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Functional dyspepsia with impaired gastric motility.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}